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AbstrAct:
Melanoma remains as the deadliest form of skin cancer with limited and inefficient 
treatment options available for patients with metastatic disease. Within the last 
decade, the thrombin receptor, Protease Activated Receptor-1, has been described as 
an essential gene involved in the progression of human melanoma. PAR-1 is known to 
activate adhesive, invasive and angiogenic factors to promote melanoma metastasis. 
It is overexpressed not only in metastatic melanoma cell lines but is also highly 
expressed in metastatic lesions as compared to primary nevi and normal skin. Recently, 
PAR-1 has been described to regulate the gap junction protein Connexin 43 and the 
tumor suppressor gene Maspin to promote the metastatic melanoma phenotype. 
Herein, we review the role of PAR-1 in the progression of melanoma as well as utilizing 
PAR-1-regulated genes as potential therapeutic targets for melanoma treatment.
MelAnoMA of the skin
In the United States, more than 68,000 new cases 
of melanoma were estimated to be diagnosed in 2010, 
continuing the trend of increased melanoma incidence 
seen over the past 40 years [1]. Melanoma is the fifth 
most commonly diagnosed type of cancer in men and 
seventh most common in women [1]. The lifetime risk of 
an American developing invasive melanoma is 1 in 55 as 
compared to 1 in 1,500 in the 1930s [2, 3]. More than 80% 
of melanomas are diagnosed at an early clinical stage 
(before regional metastasis) with more than 95% 5-year 
survival rates for patient’s with localized melanoma [2, 
4]. However, when melanoma has spread to regional 
lymph nodes or metastasized to other organs, there is 
a  significant  decrease  in  survival.  The  5-year  survival 
rate for melanoma patients with distant metastasis is 
significantly  decreased  to  15%  [2].  Therefore,  it  is 
imperative to determine the molecular events that lead to 
melanoma metastasis in search for possible therapeutic 
molecular targets to curtail the disease. 
Early stage melanoma is easily treatable and 
highly curable with surgical resection [5]. However, 
once melanoma has metastasized, there are limited and 
ineffective treatment options available for patients [5, 
6]. Decarbazine (DTIC) is the only FDA-approved 
chemotherapeutic agent for the treatment of metastatic 
melanoma despite response rates of only 15-20% [5, 
6]. Furthermore, the duration of the response to DTIC 
is not sustained, often lasting as brief as 5 months, with 
only 5% of patients showing a complete response [7, 8]. 
Clinical studies utilizing adjuvant immunotherapies with 
interferon α for high-risk stages II and III melanoma, as 
well as treatment with high-dose interleukin (IL)-2 for 
stage IV melanoma, showed limited response rates of less 
than 15% [9-12]. Identification of melanoma oncogenes, 
tumor suppressor genes and information gathered from 
microarrays have advanced our understanding of the 
molecular mechanisms of melanoma [6]. Further studies 
in these areas will allow for a clearer understanding of 
the process of melanoma progression that might lead to 
the development of urgently needed clinical therapies for 
metastatic melanoma. 
Our laboratory has been studying novel targets 
involved in the progression of melanoma to develop 
better therapeutic targets for metastatic melanoma. One of 
these genes that plays a key role in the progression from 
non-metastatic to metastatic melanoma is the thrombin 
receptor, Protease Activated Receptor-1 (PAR-1).
PAr-1
PAR-1 has been found to be involved in the Oncotarget 2011; 2:  8 - 17 9 www.impactjournals.com/oncotarget
progression of several cancers including breast [13, 
14], colon [15, 16] prostate [17, 18] and melanoma [19-
22]. As  such,  PAR-1  has  significant  roles  not  only  in 
coagulation, wound healing and inflammation, but also in 
the progression of several cancer types. PAR-1 was first 
identified by Vu et al. in 1991 [23] and remains the most 
studied and best characterized protease-activated receptor.
The thrombin receptor belongs to a family of seven 
transmembrane G-protein-coupled receptors with a unique 
method of activation. Unlike typical ligand-binding 
interactions that occur with other types of G-protein 
receptors, PAR-1 activation occurs through proteolytic 
cleavage of the N-terminal domain of the receptor by 
serine proteases. Although thrombin is the most effective 
and potent activator of PAR-1, activation can occur 
through other ligands, such as coagulation factor Xa, 
trypsin, granzyme A and plasmin [24, 25]. PAR-1 can 
also be proteolytically cleaved and activated by matrix 
metalloprotease-1 (MMP-1) in breast cancer cells [26]. 
PAR-1 activation by thrombin involves the anion-binding 
exosite of thrombin binding to the PAR-1 amino terminus 
in an acidic region spanning amino acids 51 to 63 [23]. 
This highly acidic region, termed the hirudin-like binding 
site, is similar to the amino acid sequence of the leech 
anticoagulant peptide, hirudin [27]. This region increases 
the affinity and potency of thrombin for PAR-1 [27]. PAR-
1 also contains a thrombin cleavage site between Arginine 
at position 41 and Serine at position 42 in the PAR-1 
sequence. Thrombin proteolytically cleaves the PAR-1 
N-terminus in an irreversible manner, thereby forming a 
new amino terminus with Serine 42 acting as a tethered 
ligand to activate the receptor [23, 28] (Figure 1)
Once activated, PAR-1 signals through the activated 
G-protein  subtypes,  Gαq,  Gαi,  Gα12,13,  and  Gβγ 
resulting in downstream activation of several signal 
transduction pathways, such as the phosphoinositide-3 
(PI-3) kinase, the mitogen-activated protein (MAPK) 
kinase, Rho kinases, as well as increases intracellular Ca2+ 
and activation of protein kinase C (PKC) [29] (Figure 
1). PAR-1 is primarily involved in mediating the effects 
of thrombin, which is recognized as a potent mitogen 
in cancer and tumor metastasis through sustained ERK 
1/2 activation [30]. Protease-Activated Receptors can 
also signal in response to proteases that stem from the 
figure 1: Activation and signaling of PAr-1. Thrombin, the most potent activator of PAR-1, binds to the hirudin-like binding domain on 
the N-terminus of the receptor and proteolytically cleaves between Arg 41 and Ser 42 in an irreversible manner. Ser 42 now acts as a tethered 
ligand to activate PAR-1. PAR-1 signals through G-protein subtypes, Gαq, Gαi, and Gβγ to activate PKC and MAPK, inhibit adenylyl cyclase 
as well as activate PI3-K and PKB.Oncotarget 2011; 2:  8 - 17 10 www.impactjournals.com/oncotarget
tumor and the tumor microenvironments such as MMP-
1 [26]. Activation of PAR-1 by thrombin also results 
in overexpression and secretion of pro-angiogenic and 
invasive factors such as IL-8, VEGF, PDGF2 and MMP-2 
[31].
PAr-1 in MelAnoMA
Thrombin generation occurs through multiple 
pathways including the activation of coagulation factors 
often seen in several cancer types, thereby leading to 
PAR-1 signaling [31]. In melanoma, as well as in other 
cancers, tissue factor (TF), an initiator of the coagulation 
cascade, has been found to be upregulated [32]. This 
results in expression of thrombin by activation of the 
coagulation factor X through expression of tissue factor 
[32]. Furthermore, several studies have also demonstrated 
that TF is constitutively expressed in melanoma cells 
and can activate thrombin in a coagulation-independent 
manner, thereby promoting melanoma metastasis through 
PAR-1 activation [33, 34]. Moreover, thrombin activation 
results  in  the  cleavage  of  fibrinogen  into  fibrin. These 
fibrin deposits are located in the tumor microenvironment 
and store active thrombin that is released upon degradation 
of fibrin by plasmin [31, 35, 36]. 
In an experimental murine lung metastasis model of 
melanoma, B16F10 murine melanoma cells transfected 
with the PAR-1 gene resulted in a 40-fold increase in 
pulmonary metastasis, thus demonstrating that PAR-1 was 
the rate-limiting factor in thrombin-enhanced pulmonary 
metastasis [37]. Conversely, when B16F10 cells were 
treated with a specific thrombin inhibitor, cell migration 
was suppressed and in vivo metastasis was decreased [38]. 
PAR-1 has also been found to be overexpressed in 
human metastatic melanoma cell lines as compared to 
non-metastatic cell lines [21]. Furthermore overexpression 
of PAR-1 is predominantly seen in malignant melanoma 
tumor specimens and in metastatic lesions as compared 
to benign nevi and normal skin by immunohistochemistry 
[20]. Utilizing an automated quantification laser scanning 
cytometer on a tissue microarray platform, our laboratory 
has also found a significantly higher percentage of PAR-1 
positive cells in metastatic melanoma as compared to both 
dysplastic nevi and primary melanomas [22].
trAnscriPtionAl regulAtion of 
PAr-1 in MelAnoMA
The transition from the radial growth phase to 
the vertical growth phase in the progression of human 
melanoma is associated with the loss of the transcription 
factor  Activator  Protein-2α  [39-41].  Loss  of  AP-2α 
correlates with a concomitant increases in PAR-1 
expression [21]. 
Analysis of the PAR-1 promoter region reveals 
multiple AP-2α and SP-1 binding sites as well as two 
overlapping SP-1 and AP-2α transcription factor binding 
motifs within the proximal 3’ region, thereby suggesting 
that these transcription factors mediate PAR-1 promoter 
activity [42]. Utilizing ChIP analysis, Tellez et al. 
demonstrated that AP-2α is bound to the PAR-1 promoter 
in low and non-metastatic melanoma cell lines while SP-1 
is bound to PAR-1 in metastatic melanoma cell lines [21]. 
Furthermore, it was seen that AP-2α and SP-1 bind in a 
mutually exclusive manner in one of the overlapping 
binding regions [21]. Thus, in melanoma, the low levels 
of AP-2α enable SP-1 to bind to its motif in the PAR-1 
promoter, which results in PAR-1 gene activation. Non-
metastatic melanoma cells express AP-2α. In these cells, 
the PAR-1 promoter is bound by the AP-2α transcription 
factor thereby suppressing PAR-1 gene expression [21]. 
in vivo effects of silencing PAr-1
Recently, utilizing lentiviral based shRNA, we 
stably silenced PAR-1 by more than 80% in two human 
metastatic melanoma cell lines, A375SM and C8161 
(high expressors of PAR-1), and injected these cells 
subcutaneously (to assess tumor growth) and intravenously 
(to assess experimental lung metastasis formation). We 
found significant decreases in tumor growth of PAR-1-
silenced melanoma cells as compared to cells transduced 
with a non-targeting (NT) control shRNA. Moreover, 
significant  inhibition  of  experimental  lung  metastasis 
formation was detected in PAR-1-silenced cells [43]. 
Although significant differences were seen in vivo, 
the use of a lentiviral delivery system as a therapeutic 
modality for the delivery of shRNA in melanoma or 
other cancers brings about several problems including 
the possibility of viral integration into an area where off-
target gene expression can be affected thereby leading to 
the development of diseases or cancer. Furthermore, the 
shuttling system that moves the shRNA from the nucleus 
into the cytoplasm for processing and gene silencing has 
the potential to be overwhelmed, such that exportin-5, 
involved in shRNA and miRNA shuttling, might be 
overloaded and fail to export essential miRNAs or other 
factors needed for normal cell functioning [44]. Moreover, 
for shRNA to be processed, Dicer must be present in cells. 
Merritt et al. found that Dicer expression was variable 
among ovarian cancer specimens and further demonstrate 
that  low-Dicer  expressing  cells  failed  to  significantly 
silence target genes when utilizing shRNA [45]. For 
effective use of lentiviral based shRNA, the consistent 
expression of Dicer must be present for gene silencing to 
occur. 
Thus, the use of viruses as a delivery tool for 
clinical therapies has several adverse effects including 
toxicities, overwhelming nuclear export mechanisms, as 
well as unwanted and unpredictable genetic alterations 
after viral integration [46, 47]. In recent years, much 
research has gone into finding not only effective but also Oncotarget 2011; 2:  8 - 17 11 www.impactjournals.com/oncotarget
safer alternative technologies to deliver siRNA to tumors 
including nano-liposomes [47, 48]. 
Liposomes are lipid vesicles that allow for the 
entrapment of not only siRNA but also various types of 
drugs or small molecules. By incorporating siRNAs into 
liposomes, they are protected from degradation and thus, 
the half-life and potency of the siRNA is increased [49]. 
Within the last 5 years, the use of siRNA packaged into 
neutral 1,2 dioleoyl-sn-glycero-3-phosphatidylcholine 
(DOPC) liposomes have been utilized effectively in vivo 
against EphA2 and FAK to treat ovarian cancer [50, 51] 
as well as neuropilin 2 for the treatment of colorectal 
carcinoma [52]. These studies demonstrated effective 
silencing of target genes with limited toxicities utilizing 
low-dose siRNA-DOPC delivered via intraperitoneal 
injections [48, 50]. The liposomes were found to rapidly 
enter the liver, spleen, kidney and reticuloendothelial 
system (RES) along with the target tissue [47]. 
Nevertheless, the target genes were silenced in vivo, 
demonstrating the effectiveness of this delivery system 
as a potential therapeutic modality in cancer and other 
diseases.
Although we showed that metastatic melanoma cell 
lines transduced with lentiviral-based PAR-1 shRNA lost 
their potential in forming melanoma tumors and metastatic 
lung colonies, the goal of most melanoma research is now 
aimed at developing therapies from the benchside to the 
clinic. Because of this, we wanted to use siRNA-DOPC 
nano-liposomes as an alternative delivery system that is 
safer and more feasible, yet effective.
Similar to the results obtained using lentiviral 
based silencing of PAR-1, we saw a significant decrease 
in melanoma tumor growth and experimental lung 
metastasis in melanoma tumor-bearing mice treated with 
PAR siRNA-DOPC as compared to NT siRNA-DOPC-
treated mice [43]. Moreover, Tumors from PAR-1 siRNA-
DOPC and NT siRNA-DOPC-treated mice were analyzed 
for invasive and angiogenic factors including MMP-2, 
IL-8 and VEGF. Immunohistochemical analysis revealed 
a decrease in these angiogenic and invasive factors after 
PAR-1 silencing. Furthermore, through CD31 staining, 
we observed a decrease in the number of blood vessels in 
PAR-1-silenced tumors as compared to NT siRNA-DOPC 
treated mice. In contrast, blood vessels were largely 
dilated in NT siRNA-DOPC tumors. 
It is important to note that the PAR-1 siRNA 
entrapped in the DOPC liposomes is not targeted 
specifically to the tumor cells. Our experiments however, 
utilized  a  PAR-1  sequence  specific  for  human  PAR-1 
that would not recognize murine PAR-1. Furthermore, 
PAR-1 is not expressed on mouse platelets and plays 
no role in platelet aggregation. Although this was 
beneficial for our experimental design, it did not allow 
us to determine possible side effects of systemic delivery 
of PAR-1 siRNA in terms of platelet aggregation or 
coagulation. Nevertheless, the use of PAR-1 siRNA 
might still offer a plausible therapeutic target as PAR-1 
does not interfere with thrombin generating fibrin (which 
subsequently forms a clot) nor does it interfere with other 
mechanisms that activate platelets, such as coming into 
contact with collagen from damaged blood vessels [53]. 
Furthermore, platelets can be activated by PAR-4 at higher 
concentrations of thrombin [29]. Therefore, a decrease in 
PAR-1 might not have such severe effects on coagulation 
as compared with other antithrombotic agents [53]. This 
could be corroborated by silencing the human PAR-1 
equivalent in mice, PAR-3, with systemically delivered 
siRNA-DOPC in vivo.  
Nevertheless, we sought to elucidate novel 
downstream target genes of PAR-1 that might not only 
increase our understanding of the mechanisms by which 
PAR-1 affects melanoma growth and metastasis, but 
might also be targeted by siRNA-DOPC therapies. 
regulAtion of connexin 43 by PAr-
1
To identify downstream target genes of PAR-1 that 
might contribute to the metastatic phenotype of melanoma, 
our laboratory performed cDNA microarray studies. This 
strategy led us to identify Connexin 43 (Cx-43) as a target 
gene of PAR-1 [54].
Intracellular membrane channels called connexins 
not only allow for the passage of molecules less than 
1.2 kD to pass between adjacent cells but have also 
been described to function as membrane proteins with 
adhesive properties [55, 56]. The attachment of tumor 
cells in transition from a primary site to a secondary 
organ site requires the attachment as well as the migration 
of tumor cells through the vascular endothelium. This 
communication between tumor cells and endothelial cells 
has been shown to be mediated by connexins and are 
critical to tumor cell extravasation at the metastatic site 
[57-59]. 
Increased Cx-43 expression has been observed in 
several cancers, including breast cancer [60] and gliomas 
[55]. In fact, decreased Cx-43 expression reduced adhesion 
of breast cancer cells to the pulmonary endothelium. [61]. 
In melanoma, increased coupling of Cx-43-expressing 
murine melanoma cells to vascular endothelial cells was 
previously reported [57]. However, the mechanism by 
which Connexin 43 was regulated had not been described. 
Utilizing our stably transduced PAR-1 shRNA cells, 
we found a significant decrease in Cx-43 expression after 
PAR-1 silencing as a result of decreased binding of SP-1 
and AP-1 to the Connexin 43 promoter [54]. Moreover, we 
found that silencing PAR-1 results in decreased binding 
of metastatic melanoma cell lines to human vascular 
endothelial cells and to human dermal microvascular 
endothelial cells. Upon re-expressing PAR-1 in PAR-1-
silenced cell lines, an increase in attachment was observed. 
To corroborate that the changes in attachment were due Oncotarget 2011; 2:  8 - 17 12 www.impactjournals.com/oncotarget
to Connexin 43, we stably silenced Cx-43 in metastatic 
melanoma cell lines and found decreased attachment of 
melanoma  cells  to  endothelial  cells. This  was  the  first 
report of PAR-1 regulating Cx-43 expression adding an 
alternative mechanism to how PAR-1 contributes to the 
metastatic melanoma phenotype [54]. 
However, the role of Connexin 43 in melanoma 
remains controversial. In contrast, to our findings, Cx-
43 had previously been found to be decreased in human 
melanoma cells [62, 63]. These studies focused on the 
early events involved in melanoma progression in which 
melanocytes come into contact with keratinocytes via Cx-
43 and Cx-26. They further showed that melanoma cells 
having low Connexin levels were less able to attach to 
keratinocytes thereby losing their regulation. These studies 
did not utilize melanoma cells that had developed the 
capability of metastasizing and in route to the metastatic 
site. Once melanoma cells are in the circulation, some 
acquire the capability of arresting and extravasating 
through the vascular endothelium of the metastatic site. 
Connexin 43 is crucial for the communication between 
endothelial cells and tumor cells and plays a role in tumor 
cell adherence and diapedesis [54, 64].
 PAr-1 regulAtes the MAsPin 
tuMor suPPressor gene 
One  of  the  other  genes  identified  in  our  cDNA 
microarray following PAR-1 silencing was Maspin. 
Maspin was increased by more than 45-fold as compared 
to NT shRNA transduced melanoma cells [65]. Maspin is 
a member of the serine protease inhibitor (serpin) family 
first isolated from human mammary epithelial cells [66]. 
Inhibitory serpins bind proteases to its functional domain, 
the reactive site loop (RSL). The RSL then undergoes 
cleavage by the protease which causes a conformational 
change (a stressed to relaxed conformation) in the serine 
protease inhibitor [67, 68]. The relaxed-state serpin 
complex inactivates the protease [67].
Maspin was first identified as an inhibitor of tissue-
type plasminogen activator [69] and urokinase-type 
plasminogen activator (uPA) [70, 71]. However, other 
studies have shown that Maspin does not have a direct 
serine protease inhibitor function, as its functional domain, 
the reactive site loop, does not undergo a stressed to relax 
conformational change essential for protease inhibition 
by serpins [67, 72]. Recently, Denk et al., proposed that 
in malignant melanoma, Maspin does function as an 
inhibitory serpin as it blocks matrix-degrading proteases 
[73]. 
Maspin expression has been found to be decreased 
or lost in several malignancies and is associated with 
decreased aggressiveness in prostate cancer and breast 
figure 2: PAr-1 regulates Maspin expression in melanoma. Silencing PAR-1 results in decreased activation of p38 MAPK, a known 
inhibitor of CBP/p300. This results in higher levels of CBP/p300 HAT activity allowing for increased binding of c-Jun and Ets-1 transcription 
factors to the Maspin promoter. Increased Maspin expression further inhibits cell invasion, through decreased expression and activity of MMP-
2, as well as angiogenesis through decreased VEGF expression. Oncotarget 2011; 2:  8 - 17 13 www.impactjournals.com/oncotarget
cancer [74, 75]. Mammary cancer cells that were 
transfected with Maspin resulted in decreased tumor 
growth and metastasis in vivo [76]. 
On the contrary, Maspin has been found to be 
overexpressed in several cancers, including bladder [77], 
lung [78], and pancreatic [79] cancers. Furthermore, in 
ovarian cancer and colon carcinoma, overexpression 
of Maspin correlates with nuclear translocation [73, 
80, 81]. As such, Maspin also seems to have a role as a 
transcriptional regulator by increasing expression of tumor 
supportive genes [73, 80]. The nuclear Maspin found 
in ovarian cancer seems to inhibit the tumor suppressor 
cytoplasmic functions of Maspin [73, 81]. Thus, the role 
of Maspin in cancer seems to be tumor type specific and 
depends on its intracellular localization. 
Maspin was recently found to be a tumor suppressor 
in melanoma. Metastatic melanoma cells were found to 
have decreased expression levels of Maspin as compared to 
normal human epidermal melanocytes [73]. Furthermore, 
this study found that when Maspin was re-expressed in 
melanoma cells, there was a significant reduction in their 
invasive capacity. 
The mechanism of Maspin regulation, however, has 
not been described for melanoma. It has been hypothesized 
that the loss of Maspin in metastatic melanoma tumor 
specimens might be attributed to an increase in p53, as there 
is evidence showing overexpression of p53 in metastatic 
melanoma specimens [82-84]. Furthermore, in several 
cancers such as breast and prostate cancers, an inverse 
correlation between p53 and Maspin expression has been 
suggested [85, 86]. However, Webber and colleagues 
found no correlation between p53 and Maspin expression 
when analyzing metastatic melanoma specimens. Thus, 
the mechanism for Maspin regulation in melanoma has 
yet to be elucidated [84].
Our laboratory recently published our findings on 
PAR-1 regulation of the Maspin tumor suppressor gene 
in melanoma [65]. We found an inverse correlation 
between PAR-1 and Maspin expression. Highly metastatic 
melanoma cell lines have high PAR-1 expression and low 
Maspin levels. Likewise, silencing PAR-1 via lentiviral 
shRNA, results in increased Maspin expression levels 
through increased binding of two transcription factors 
known to regulate Maspin, c-Jun and Ets-1. Interestingly, 
we did not see a difference in protein expression of c-Jun 
and Ets-1 after PAR-1 silencing. Rather, we found that 
silencing PAR-1 inhibits phospho- p38 MAPK which 
releases the inhibition of the histone acetlytransferase 
CBP/p300. The increased HAT activity allows for 
increased binding of Ets-1 and c-Jun to the Maspin 
promoter and subsequently increased Maspin expression. 
Our studies further found that the increased in Maspin 
expression results in a decrease in invasion by inhibiting 
MMP-2 expression and activity (Figure 2). In vivo studies 
utilizing Maspin expression vectors showed a significant 
decrease in melanoma tumor growth and experimental 
lung metastasis as well as decreased MMP-2, VEGF, and 
Maspin expression levels from tumor sections. To further 
corroborate that PAR-1 was regulating Maspin expression 
in vivo, we stably silenced Maspin in PAR-1-silenced cell 
lines and showed that levels of melanoma tumor growth 
and experimental lung metastasis were similar to Non-
Targeting shRNA-transduced control cells. Furthermore, 
levels of Maspin, VEGF and MMP-2 were also increased 
to levels similar to NT-transduced cells [65].
clinicAl iMPlicAtions
Identifying PAR-1 and its downstream target genes, 
Connexin 43 and Maspin, as factors involved in melanoma 
progression is essential, as current therapies for metastatic 
melanoma  are  not  efficient.  The  only  FDA  approved 
chemotherapeutic agent is Decarbazine even with dismal 
response rates of 15% [5, 6]. Furthermore, the duration of 
the response to DTIC is not sustained, often lasting as brief 
as 5 months [5, 7, 8]. Adjuvant therapies with interferon 
α  or  IL-2  for  high  stage  melanoma  patients  also  have 
limited response rate of less than 20% [9-12] . Our studies 
suggest that targeting PAR-1 can potentially be used as a 
target for human melanoma therapy. Furthermore, PAR-1 
regulates multiple genes essential for melanoma growth 
and metastasis such as Connexin 43 which could also 
potentially serve as novel targets for melanoma therapies. 
Nevertheless using a single target for therapy has not had 
success in melanoma. Combining PAR-1 targeted therapy 
with chemotherapy, anti-angiogenic drugs, pro-apoptotic 
drugs, or even HDAC inhibitors could potentiate the 
anti-tumor and anti-metastatic effects seen in our PAR-
1 studies. Finding the right combination of therapies to 
effectively treat metastatic melanoma remains one of 
the biggest challenges in melanoma research, especially 
in melanoma cells that do not harbor the BRAF V600E 
mutation.
Although our studies focus on the effects of PAR-1 
on melanoma progression, several other cancers such as 
breast, prostate, colon and pancreatic cancers have been 
found to have increased PAR-1 expression with increased 
progression of disease. As such, targeting PAR-1 in these 
cancers could also have therapeutic potential. 
Taken together our studies show that PAR-1 plays 
a major role in melanoma progression and that targeting 
PAR-1 or its downstream target genes could help in 
treating metastatic melanoma and could have potential 
benefits in treating several other cancer types as well. 
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